Revance Therapeutics, Inc. (RVNC)
USD 3.07
(0.0%)
USD 3.07
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 234.04 Million | 132.56 Million | 77.79 Million | 15.32 Million | 413 Thousand | 3.72 Million |
| Cost of Revenue | 152.16 Million | 51.66 Million | 23.41 Million | 4.76 Million | 102.86 Million | 92.5 Million |
| Gross Profit | 81.87 Million | 80.89 Million | 54.38 Million | 10.55 Million | -102.44 Million | -88.77 Million |
| Operating Expenses | 398.65 Million | 353.06 Million | 329.06 Million | 283.71 Million | 164.87 Million | 146.36 Million |
| Selling, General and Administrative Expenses | 292.23 Million | 223.93 Million | 198.82 Million | 151.84 Million | 62.01 Million | 53.86 Million |
| Research and Development Expenses | 79.41 Million | 101.28 Million | 116.25 Million | 125.79 Million | 102.86 Million | 92.5 Million |
| Other Expenses | 27 Million | 27.84 Million | 13.98 Million | 6.07 Million | -303 Thousand | -773 Thousand |
| Cost and Expenses | 550.81 Million | 404.73 Million | 352.47 Million | 288.48 Million | 164.87 Million | 146.36 Million |
| Operating Income | -316.77 Million | -272.16 Million | -274.67 Million | -273.16 Million | -164.45 Million | -142.63 Million |
| Interest Expense | 19.35 Million | 16.47 Million | 6.27 Million | 15.14 Million | - | 44 Thousand |
| Income Tax Expense | 300 Thousand | 700 Thousand | 5.51 Million | -2.62 Million | -3.21 Million | 3 Million |
| Earnings before Tax | -323.68 Million | -355.72 Million | -281.31 Million | -284.7 Million | -159.42 Million | -139.56 Million |
| Net Income | -323.98 Million | -356.42 Million | -286.82 Million | -282.08 Million | -156.21 Million | -142.56 Million |
| Earnings Per Share Basic | -3.83 | -4.90 | -4.25 | -4.86 | -3.59 | -3.94 |
| Earnings Per Share Diluted | -3.83 | -4.90 | -4.25 | -4.86 | -3.59 | -3.94 |
| Weighted Average Shares Outstanding | 84.59 Million | 72.71 Million | 67.5 Million | 58 Million | 43.46 Million | 36.17 Million |
| Weighted Average Shares Outstanding (Diluted) | 84.59 Million | 72.71 Million | 67.5 Million | 58 Million | 43.46 Million | 36.17 Million |
| Gross Margin | 0.35 | 0.61 | 0.70 | 0.69 | -248.06 | -23.81 |
| EBIT Margin | -1.24 | -1.82 | -3.36 | -17.18 | -385.54 | -37.38 |
| Profit Margin | -1.38 | -2.69 | -3.69 | -18.41 | -378.25 | -38.23 |
| EBITDA | -290.63 Million | -305.51 Million | -255.18 Million | -259.31 Million | -156.52 Million | -137.79 Million |
| Earnings Before Tax Margin | -1.35 | -2.05 | -3.53 | -17.82 | -398.21 | -38.25 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 65.38 Million | 51.93 Million | 69.79 Million | 234.04 Million | 56.77 Million | 58.13 Million |
| Cost of Revenue | 19.06 Million | 16.89 Million | 18.89 Million | 88.05 Million | 19.41 Million | 21.3 Million |
| Gross Profit | 46.32 Million | 35.04 Million | 50.9 Million | 145.98 Million | 37.36 Million | 36.82 Million |
| Operating Expenses | 80.9 Million | 81.1 Million | 104.01 Million | 366.7 Million | 82.74 Million | 102.32 Million |
| Selling, General and Administrative Expenses | 65.41 Million | 67.47 Million | 84.29 Million | - | 67.72 Million | 77.38 Million |
| Research and Development Expenses | 15.48 Million | 13.62 Million | 19.72 Million | - | 13.06 Million | 22.8 Million |
| Other Expenses | -453 Thousand | -438 Thousand | 218 Thousand | -838 Thousand | -223 Thousand | -599 Thousand |
| Cost and Expenses | 99.96 Million | 97.99 Million | 122.9 Million | 454.76 Million | 102.15 Million | 123.63 Million |
| Operating Income | -34.57 Million | -46.06 Million | -53.1 Million | -220.72 Million | -139.29 Million | -65.49 Million |
| Interest Expense | 5.67 Million | 5.25 Million | 5.39 Million | 19.35 Million | 5.09 Million | 4.36 Million |
| Income Tax Expense | 1000.00 | 3.62 Million | 1.37 Million | 300 Thousand | 300 Thousand | -64 Thousand |
| Earnings before Tax | -37.46 Million | -49.52 Million | -55.69 Million | -323.68 Million | -140.87 Million | -67.31 Million |
| Net Income | -37.47 Million | -53.15 Million | -55.69 Million | -323.98 Million | -141.17 Million | -67.31 Million |
| Earnings Per Share Basic | -0.36 | -0.58 | -0.62 | - | -1.63 | -0.80 |
| Earnings Per Share Diluted | -0.36 | -0.58 | -0.62 | - | -1.63 | -0.80 |
| Weighted Average Shares Outstanding | 103.87 Million | 91.91 Million | 90.14 Million | 84.59 Million | 86.61 Million | 83.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 103.87 Million | 91.91 Million | 90.14 Million | 84.59 Million | 86.61 Million | 83.68 Million |
| Gross Margin | 0.71 | 0.67 | 0.73 | 0.62 | 0.66 | 0.63 |
| EBIT Margin | -0.51 | -0.85 | -0.74 | - | -0.70 | -1.05 |
| Profit Margin | -0.57 | -1.02 | -0.80 | -1.38 | -2.49 | -1.16 |
| EBITDA | -33.14 Million | -44.08 Million | -51.68 Million | - | -39.74 Million | -60.81 Million |
| Earnings Before Tax Margin | -0.53 | -0.89 | -0.76 | -0.94 | -2.45 | -1.13 |
002015
LOV
CVS
RMC
HNR1
300833